Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 07-22 16:51:36时区推断·⟳ 抓取 07-22 16:58:06·⚡ 决策 07-23 09:03:18 +16h05m·96.6 天前
特朗普威胁2028年起对未在美生产仿制药征100%至200%关税，Sandoz称将继续沟通
政策威胁指向未在美国本土生产的仿制药，Sandoz北美销售约占22%，且此前计划2026年底关闭唯一美国生产基地。
📄 原文Investing.com↗ 原文
Generic drugmaker Sandoz to engage with US after Trump tariff threat
Oil hovers near six-week high as expanding Mideast conflict fuels supply fears By Marleen Kaesebier ZURICH, July 22 (Re…
不做 Sandoz（SDZNY.US）
方向偏空但关税最早2028年才生效、政策细则未定，且SDZNY.US未取得真实报价和借券状态，不能开空；仅保留风控风险信号。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 high · price-in 风险 medium ↗
消息传播链
- 2026-07-21首发X/Trump post声称一手 · 未核验特朗普在X发帖威胁仿制药厂若不在美国本土生产，将从2028年8月起面临100%关税，下一年升至200%。
- Reuters报道Sandoz回应称将继续与政策制定者沟通，并称评估影响仍太早。市场反应:报道称Sandoz开盘后跌约3%。
关键理由
- 政策威胁指向未在美国本土生产的仿制药，Sandoz北美销售约占22%，且此前计划2026年底关闭唯一美国生产基地。
- 事件时间在2028年8月之后才可能生效，且公司称现在评估运营或投资影响仍太早。
主要风险
- 这是长期政策威胁而非已落地处罚，细则和豁免空间大；SDZNY.US工具未取得真实报价，不能给可执行空单。
反向证据
- 做空前查反向 · 来源 kb_search · 日期 2026-07-22 · 影响 weakens
内部库命中券商认为Hikma/Fresenius因美国制造布局更具优势，确认该政策主要是相对生产布局压力；但政策远期、细则未定。
检索:Sandoz generic drug tariff 100% 200% Trump North America sales production United States 原文 ↗ - 做空前查反向 · 来源 stock_quote · 日期 2026-07-23 · 影响 invalidates
行情工具对SDZNY.US返回no_price，无法确认真实价和借券状态。
检索:SDZNY.US
工具调用 · 历史记录,结果未知(4 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,695 字
Oil hovers near six-week high as expanding Mideast conflict fuels supply fears
By Marleen Kaesebier
ZURICH, July 22 (Reuters) - Swiss generic drugmaker Sandoz said on Wednesday it would continue discussions with policymakers after U.S. President Donald Trump threatened the industry with steep tariffs unless drugmakers manufacture medicines domestically.
Trump said in a post on X on Tuesday that generic drugmakers will have to manufacture medicines for the U.S. locally or be hit with a 100% tariff from August 2028 followed by a 200% tariff starting the year after.
More than 90% of medicines sold in the U.S. are generics, according to the U.S. Food and Drug Administration.
"We share the goal of improving affordability and access to medicines in the United States," Sandoz said in a statement. It added it would continue discussions with policymakers on how to best achieve this, as first reported by the Wall Street Journal.
Sandoz said in 2024 that it would close its only U.S. manufacturing site on Long Island, New York, around the end of 2026. It said it was too early to assess any implications for manufacturing operations or future investment decisions.
Vontobel analyst Stefan Schneider said the U.S. government is aiming to reverse the shift of generic drug production to lower-cost countries, although bringing manufacturing back would likely raise generic drug prices in the United States.
He added that any new rules would predominantly affect China and India, where most generic drugs are manufactured, but would also weigh on Sandoz, with around 22% of its sales in North America and little production there.
Sandoz shares fell around 3% after the market open on Wednesday.
By Marleen Kaesebier
ZURICH, July 22 (Reuters) - Swiss generic drugmaker Sandoz said on Wednesday it would continue discussions with policymakers after U.S. President Donald Trump threatened the industry with steep tariffs unless drugmakers manufacture medicines domestically.
Trump said in a post on X on Tuesday that generic drugmakers will have to manufacture medicines for the U.S. locally or be hit with a 100% tariff from August 2028 followed by a 200% tariff starting the year after.
More than 90% of medicines sold in the U.S. are generics, according to the U.S. Food and Drug Administration.
"We share the goal of improving affordability and access to medicines in the United States," Sandoz said in a statement. It added it would continue discussions with policymakers on how to best achieve this, as first reported by the Wall Street Journal.
Sandoz said in 2024 that it would close its only U.S. manufacturing site on Long Island, New York, around the end of 2026. It said it was too early to assess any implications for manufacturing operations or future investment decisions.
Vontobel analyst Stefan Schneider said the U.S. government is aiming to reverse the shift of generic drug production to lower-cost countries, although bringing manufacturing back would likely raise generic drug prices in the United States.
He added that any new rules would predominantly affect China and India, where most generic drugs are manufactured, but would also weigh on Sandoz, with around 22% of its sales in North America and little production there.
Sandoz shares fell around 3% after the market open on Wednesday.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。